The main targets for the effect of LOLA according to current evidence are the urea cycle enzymes CPS1 and OTC, whose expression was elevated in hepatocytes from NASH patients when compared to those from NAFL patients. Here, CPS1 is linked to metabolic dysfunction-associated steatohepatitis.